BeStock  
Stocks › Biotechnology › TRAX

First Tracks Biotherapeutics TRAX

US equityMarket cap rank #2772Biotechnology
$41.64 −$2.82 (-6.34%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $40.70 -2.26%
Open$43.99
Prev close$44.46
Day range$41.23 – $44.74
Volume504.4K
Market cap$1.75B
P/E (TTM)–
Dividend yield–

Fundamentals

Latest reported quarter: Q3, ended Sep 2026

Revenue$0.00
Operating profit-$32.84M+27.1% YoY
Net profit-$31.36M+25.1% YoY
Diluted EPS-$0.88+26.9% YoY
Free cash flow-$17.05M+44.5% YoY
Operating cash flow-$17.05M

Revenue, last 6 quarters

$0.0Mar '25$0.0Jun '25$0.0Sep '25$0.0Mar '26$0.0Jun '26$0.0Sep '26

Net profit, last 6 quarters

$-47.2MMar '25$-42.4MJun '25$-41.9MSep '25$-50.5MMar '26$-33.4MJun '26$-31.4MSep '26

Diluted EPS by quarter

-1.36Mar '25-1.22Jun '25-1.20Sep '25-1.45Mar '26-0.95Jun '26-0.88Sep '26

Free cash flow by quarter

$-45.0MMar '25$-38.7MJun '25$-30.7MSep '25$-32.6MMar '26$-31.9MJun '26$-17.1MSep '26

Profitability & balance sheet

Current ratio9.16
Liabilities / assets11.4%
Cash & investments$155.63M
Total debt$1.36M
Net cash (debt)$154.27M

Income statement

Line item 2026 Q3 2026 Q2 2026 Q1 2025 Q3 2025 Q2
Total Operating Revenue $0.00 $0.00 $0.00 $0.00 $0.00
Other Income (Expense) -$7,000.00 -$1,000.00 -$1,000.00 – -$13,000.00
Operating Expense $32.84M $34.94M $52.81M $45.06M $45.90M
Selling and Admin Expenses $9.00M $9.29M $18.86M $11.74M $6.63M
-General & Admin Expense $9.00M $9.29M $18.86M $11.74M $6.63M
Research & Development $23.85M $25.64M $33.96M $33.32M $39.27M
Operating Profit -$32.84M -$34.94M -$52.81M -$45.06M -$45.90M
Diluted EPS -$0.88 -$0.95 -$1.45 -$1.20 -$1.22
Net Non-Operating Interest Income (Expense) $1.50M $1.56M $2.33M $3.20M $3.47M
Non-Operating Interest Income $1.50M $1.56M $2.33M $3.20M $3.47M
Other Non-Operating Income (Expenses) -$7,000.00 -$1,000.00 -$1,000.00 – -$13,000.00
Pretax Profit -$31.36M -$33.37M -$50.48M -$41.86M -$42.45M
Net Profit -$31.36M -$33.37M -$50.48M -$41.86M -$42.45M
Profit from Continuing Operations -$31.36M -$33.37M -$50.48M -$41.86M -$42.45M
Net Income to Parent Company -$31.36M -$33.37M -$50.48M -$41.86M -$42.45M
Net Income to Common Stockholders -$31.36M -$33.37M -$50.48M -$41.86M -$42.45M
Basic EPS -$0.88 -$0.95 -$1.45 -$1.20 -$1.22

Balance sheet

Line item 2026 Q3 2026 Q2 2026 Q1 2024 ANNUAL 2023 ANNUAL
-Common Stock $36,000.00 $35,000.00 – – –
-Preferred Stock $0.00 $0.00 – – –
Total Assets $170.46M $183.14M $290.58M $441.89M $444.11M
Total Current Assets $165.72M $177.75M $289.40M $389.93M $398.56M
Cash and Cash Equivalents & Short-Term Investments $155.63M $168.02M $286.46M $385.37M $390.90M
-Cash and Cash Equivalents $155.63M $168.02M $248.47M $123.08M $35.97M
-Short Term Investments $0.00 $0.00 $37.99M $262.29M $354.94M
Receivables $2.87M $5.07M – – –
-Other Receivables $2.87M $5.07M – – –
Prepaid Assets $5.22M $2.47M – – –
Other Current Assets $2.01M $2.18M $2.95M $4.56M $7.65M
Total Non-Current Assets $4.73M $5.40M $1.17M $51.96M $45.55M
Net PPE $4.73M $5.40M $1.17M $16.23M $18.27M
-Gross PPE $12.10M $12.67M $8.35M $22.83M $24.49M
-Accumulated Depreciation -$7.37M -$7.28M -$7.17M -$6.60M -$6.22M
Additional Paid-In Capital $206.91M $193.34M – – –
Retained Earnings -$55.93M -$24.58M – – –
Gains/Losses Not Affecting Retained Earnings $0.00 $0.00 -$146,000.00 $305,000.00 -$797,000.00
Short-Term Debt and Capital Lease Obligation $2.42M $2.44M – $1.93M $1.78M
Current Accrued Expenses $7.59M $5.49M $20.76M $23.05M $9.43M
-Accounts Payable $3.95M $2.55M $7.50M $3.79M $2.43M
Payables $3.95M $2.55M $7.50M $3.79M $2.43M
Total Current Liabilities $18.09M $12.45M $33.11M $36.18M $18.22M
-Current Capital Lease Obligation $2.42M $2.44M $0.00 $1.93M $1.78M
Total Non-Current Liabilities $1.36M $1.90M $0.00 $14.11M $16.04M
Capital Stock $36,000.00 $35,000.00 – – –
Stockholders' Equity $151.01M $168.80M $257.46M $391.60M $409.85M
Total Equity $151.01M $168.80M $257.46M $391.60M $409.85M
-Long Term Capital Lease Obligation $1.36M $1.90M $0.00 $14.11M $16.04M
Long Term Debt and Capital Lease Obligation $1.36M $1.90M $0.00 $14.11M $16.04M
Total Liabilities $19.45M $14.34M $33.11M $50.30M $34.26M
Other Equity Interests – – $257.61M $391.29M $410.65M
Other Non-Current Assets – – – $256,000.00 $256,000.00
Investments and Advances – – – $35.47M $27.03M

Cash flow

Line item 2026 Q3 2026 Q2 2026 Q1 2025 Q3 2025 Q2
Operating Cash Flow -$17.05M -$31.92M -$32.56M -$30.69M -$38.64M
Net cash flow from continuing operations -$17.05M -$31.92M -$32.56M -$30.69M -$38.64M
-Change in Prepaid Assets -$837,000.00 -$12.36M $2.16M -$1.54M $1.08M
Free Cash Flow -$17.05M -$31.94M -$32.58M -$30.70M -$38.68M
Beginning Cash Balance $168.02M $248.47M $238.20M $44.30M $98.64M
Net Change in Cash -$12.39M -$80.45M $10.27M $65.54M -$54.34M
Ending Cash Balance $155.63M $168.02M $248.47M $109.83M $44.30M
Net Income from Continuing Operations -$31.36M -$33.37M -$50.48M -$41.86M -$42.45M
Net Other Financing Charges -$486,000.00 -$235.07M $7.85M -$7.06M -$52.11M
Net Common Stock Issuance $0.00 – – $0.00 –
Net Cash Flow from Continuing Financing Activities $4.66M -$48.51M $7.85M -$7.06M -$52.11M
Financing Cash Flow $4.66M -$48.51M $7.85M -$7.06M -$52.11M
Net Investment Purchase and Sale $0.00 $0.00 $35.00M $103.29M $36.44M
Net PPE Purchase and Sale $0.00 -$25,000.00 -$17,000.00 -$12,000.00 -$39,000.00
Net Cash Flow from Continuing Investing Activities $0.00 -$25,000.00 $34.98M $103.28M $36.40M
Net cash flow from investing $0.00 -$25,000.00 $34.98M $103.28M $36.40M
-Change in Other Current Liabilities -$892,000.00 -$93,000.00 $0.00 -$490,000.00 -$479,000.00
-Change in Payables and Accrued Expense $6.14M $5.24M $4.15M $3.87M -$3.46M
Depreciation & Depletion & Amortization $993,000.00 $207,000.00 $125,000.00 $610,000.00 $601,000.00
Proceeds from Stock Option Exercised $5.15M – – $0.00 –
Change in Working Capital $4.42M -$7.22M $6.30M $1.84M -$2.85M

Discussion

No comments yet — be the first to weigh in on TRAX.

Sign in to join the discussion.

Scroll to Top